Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas-Reference-Cited by-同舟云学术

Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas

Published:2008-07-02 Issue:3 Volume:12 Page:153-157
ISSN:1386-341X
Container-title:Pituitary
language:en
Short-container-title:Pituitary

Author:

Vallette Sophie,Serri Karim,Rivera Juan,Santagata Patricia,Delorme Sophie,Garfield Natasha,Kahtani Nora,Beauregard Hugues,Aris-Jilwan Nahla,Houde Ghislaine,Serri Omar

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s11102-008-0134-2.pdf

Reference18 articles.

1. Van CG, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van ZM et al (2004) Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179–1183. doi: 10.1016/S0140-6736(04)15945-X

2. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38. doi: 10.1056/NEJMoa062222

3. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46. doi: 10.1056/NEJMoa054830

4. Colao A, Di SA, Cappabianca P, Di SC, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033. doi: 10.1056/NEJMoa022657

5. Schlechte JA (2007) Long-term management of prolactinomas. J Clin Endocrinol Metab 92:2861–2865. doi: 10.1210/jc.2007-0836

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pituitary macroadenoma with panhypopituitarism masquerading as schizophrenia: a diagnostic dilemma managed conservatively;Annals of Medicine & Surgery;2023-10-17

2. Clinical guidelines ‘Hyperprolactinemia’ (draft);Obesity and metabolism;2023-07-26

3. Approach to the Patient With Prolactinoma;The Journal of Clinical Endocrinology & Metabolism;2023-03-28

4. Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?;Endocrine Oncology;2022-05-01

5. The PRolaCT studies — a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma;Trials;2021-09-25